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ABSTRACT
Non-Hodgkin’s lymphoma (NHL) is a diverse group of lymphoid neoplasms, the prevalence of which has increased over the past few decades. NHL 
is diverse in the manner of presentation, response to various treatment and prognosis. The current case report describes a 40-year-old man who 
was diagnosed with small lymphocytic lymphoma/chronic lymphocytic leukemia in 2006. The patient had disease progression during the course of 
10 years from the time of diagnosis for which he received multiple lines of chemotherapy (chlorambucil/prednisolone; rituximab/cyclophosphamide/
fludarabine; bendamustine/rituximab; and ofatumumab). However, in 2016, his disease again showed signs of progression, and hence he was started 
on ibrutinib 140 mg 3 times daily. After treatment with ibrutinib, there were no clinical nodes and hepatosplenomegaly, and all counts also normalized. 
Since the commencement of this agent, no disease progression was observed for almost 16 months. However, in July 2017, again disease progression 
occurred, and the patient was started on with cyclophosphamide, vincristine, and prednisone (COP) regimen. He received one cycle of COP regimen 
and continued on treatment with ibrutinib, and the treatment was well tolerated. In December 2017, he expired due to the progression of the disease. 
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, appears to be safe and effective in providing long-term disease control even in refractory cases of NHL.
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INTRODUCTION
Non-Hodgkin’s lymphomas (NHLs) consist of a heterogeneous group 
of malignancies arising from lymphoid tissue, with varied clinical, 
pathological, and biological features. In India, incidence rates of 
2.9 and 1.5 per 100,000 have been reported in men and women, 
respectively [1-3]. Chronic lymphocytic leukemia (CLL) often grouped 
as NHL, is a lymphoproliferative disease that has a highly variable 
clinical course and may involve the bone marrow, blood, and solid 
lymphoid organs [4].
The therapeutic options for the management of CLL have 
advanced over the years from chemotherapy with chlorambucil, 
to chemoimmunotherapy with cyclophosphamide, doxorubicin, 
vincristine, prednisone, fludarabine, and rituximab [5]. However, 
in many patients, the presence of comorbidities, low bone marrow 
reserve, acquired genetic mutations make the treatment suboptimal 
and resulting in relapse [6]. During the recent years, research has 
focused on drugs targeting novel mechanisms such as Bruton’s tyrosine 
kinase and apoptosis proteins [4].
Ibrutinib is an orally active, irreversible covalent inhibitor of Bruton’s 
tyrosine kinase, a signaling molecule of the B-cell receptor pathway. 
Studies have demonstrated that ibrutinib prevents the activation 
of downstream pathways affected by Bruton’s tyrosine kinase and 
regulates adhesion, homing, proliferation, differentiation, and survival 
of cancerous cells [7,8]. It is Food and Drug Administration approved 
for CLL patients who have received at least one prior therapy [9]. The 
current report presents the case of a patient treated with ibrutinib at 
our center.
CASE REPORT
A 40-year-old male, with a history of swelling in the right neck 
since 3 years was admitted to our institution in July 2006. On local 
examination, multiple small swelling in the right and left side of the 
neck in the anterior and posterior triangle was observed with the 
largest measuring about 3×2 cm. Abdominal ultrasound examination 
revealed multiple para-aortic, mesenteric and iliac lymph nodes, and 
largest measuring 43×17 mm. Excision biopsy of the lymph node 
revealed small lymphocytic lymphoma/CLL. The patient received 
chemotherapy with chlorambucil and prednisolone for 2 weeks. 
In 2011, the patient had disease progression and was treated with 
six cycles of chemotherapy with rituximab/cyclophosphamide/
fludarabine, and had a progression-free survival (PFS) of 18 months. 
In November 2013, again the disease got worsened, and large 
neck nodes were evident. Hence, the patient received six cycles of 
chemotherapy with R-bendamustine and rituximab. In July 2015, the 
patient presented with complaints of low back pain, decreased urine 
output, abdominal distension, and constipation. His peripheral smear 
revealed normocytic normochromic anemia with thrombocytopenia 
with 72% mature lymphocytes. On magnetic resonance imaging 
(MRI), marrow infiltration of spine, and multiple significantly enlarged 
discrete and conglomerate intra-abdominal nodal masses were 
evident. The patient was treated with cyclophosphamide as a bridge 
to ofatumumab therapy. Following this, the patient received weekly 
ofatumumab therapy for 8 weeks without any major complaints until 
October 2015. However, in February 2016, the patient presented with 
complaints of breathlessness, hiccough, abdominal discomfort, and 
generalized weakness. Ultrasonography of abdomen showed multiple 
discrete and conglomerate hypoechoic nodes in the periportal, 
peripancreatic, para-aortic, splenic hilum, and along common iliac 
vessels. Hepatosplenomegaly was also seen. His hemoglobin level was 
8.6 g/dl; platelet count was 51 ku/ml, and total count was 74.2 ku/ml. 
In view of progression, the patient was started on ibrutinib 140 mg 
thrice daily from March 2016. After treatment with ibrutinib, there 
were no clinical nodes and hepatosplenomegaly; and all counts also 
normalized (hemoglobin level: 13.1 g/dl, platelet count: 184 ku/ ml, 
and total count: 113 ku/ml). In March 2017, he had cough with 
a minimal expectoration and breathlessness. In July 2017, he 
complained of leg pain. MRI showed marrow involvement of cervical, 
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thoracic and lumbar vertebra with epidurals of tissue component at 
D6 and D9 level causing compression of spinal cord; enlarged para-
aortic and iliac nodes and diffuse marrow involvement of pelvic bones 
and bilateral femurs with soft tissue deposits along the iliac crests. 
In view of the disease progression, the patient was started on with 
cyclophosphamide/vincristine/prednisone. In September 2017, he 
presented with complaints of pneumonia for which he was admitted 
and treated conservatively. In December 2017, he presented with 
complaints of breathlessness and expired due to progressive disease.
DISCUSSION
Lymphoma is a common hematologic malignancy. Survival rates for 
NHL have significantly improved over the past several decades, but 
patients with relapsed and refractory disease continue to do poorly. The 
prognosis is poor for most patients even with most current treatment 
regimens.
The choice of treatment depends on the patient’s age, comorbidities, 
and tolerance to chemotherapeutic agents. Ibrutinib is a recently 
approved agent that targets the B cell receptor pathway that has an 
important role in B cell maturation, proliferation, and survival. In a 
comparative phase 3 trial of ibrutinib and ofatumumab, ibrutinib at a 
daily dosage of 420 mg demonstrated higher overall response rate (43% 
vs. 4%) and improved PFS at 12 months (90% vs. 81%) [10]. In our 
patient, ibrutinib monotherapy produced a PFS of almost 16 months. 
This appears promising since our patient had an advanced disease 
profile and had received treatment with chlorambucil/prednisolone; 
rituximab/cyclophosphamide/fludarabine; bendamustine/rituximab; 
and ofatumumab before therapy with ibrutinib. Hence, if ibrutinib is 
started at an earlier stage of the disease, the better outcome can be 
expected.
In clinical studies, ibrutinib has been found to be well tolerated. The most 
common adverse events associated with ibrutinib include diarrhea, 
fatigue, cough, nausea, and upper respiratory infection. Serious adverse 
effects usually occur infrequently and include neutropenia, diarrhea, 
hypertension, fatigue, and pneumonia [11]. The patient we represented 
in this report had experienced episodes of respiratory infection, cough, 
breathlessness, and pneumonia during the therapy. These adverse 
effects may possibly be due to ibrutinib therapy.
One of the drawbacks of ibrutinib therapy is that it does not achieve 
minimal residual disease negative complete remissions and therefore 
in the majority of patients, must be given indefinitely if relapse is to be 
prevented. This can lead to a considerable cost to the patient and can 
also result in risk of toxicity such as cardiac arrhythmias, hypertension, 
and bleeding [12].
Combination of ibrutinib with other therapy such as rituximab, 
ofatumumab, ublituximab, and obinutuzumab is being explored. Our 
patient had received monotherapy with ibrutinib. In future studies, 
one needs to explore whether ibrutinib monotherapy or combination 
therapy is ideal for CLL patients. The duration of ibrutinib therapy to 
get optimum results also needs to be explored in future studies.
CONCLUSION
Ibrutinib, a Bruton’s tyrosine kinase inhibitor, appears to be safe 
and very effective in providing long-term disease control even in 
refractory cases of NHL. Since the data we represented here was only 
from a single patient, further studies with more numbers can reveal a 
better perspective regarding the safety and efficacy of ibrutinib in the 
management of NHL in the Indian population.
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